The Board of Directors of Sansure Biotech Inc. has authorized a buyback plan on March 17, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.63 CNY | -0.23% | -1.29% | -9.82% |
Jun. 12 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.82% | 1.38B | |
-4.72% | 12.35B | |
+99.06% | 8.55B | |
-22.10% | 6.6B | |
+8.48% | 5.88B | |
-22.96% | 3.52B | |
+6.08% | 2.55B | |
+38.04% | 2.39B | |
-7.04% | 2.33B | |
-68.75% | 2.09B |
- Stock Market
- Equities
- 688289 Stock
- News Sansure Biotech Inc.
- Sansure Biotech Inc. authorizes a Buyback Plan.